1045. A multicenter propensity score-adjusted retrospective study for comparison of the outcome of treatment with third-generation cephalosporin versus broad-spectrum antibiotics for Enterobacter bacteremia.
Session: Poster Abstract Session: Bacteremia and Endocarditis
Friday, October 5, 2018
Room: S Poster Hall
  • Poster_Enterobacter_IDweek2018.pdf (121.0 kB)
  • Background: Enterobacter spp. can develop resistance during prolonged therapy with third-generation cephalosporins (3GC: ceftriaxone, cefotaxime, or ceftazidime) because of derepression of AmpC b-lactamase. However, the clinical significance of this phenomena remains undetermined. This study aims to assess the outcome of patients with 3GC-susceptible Enterobacter bacteremia (EB) who received definite therapy with 3GC or broad-spectrum antibiotics (BSA) using propensity score analysis.

    Methods: In this retrospective, cohort study conducted at two tertiary care hospitals in Japan, we determined consecutive patients with EB identified from the laboratory databases between January 2010 and December 2017. We enrolled patients with 3GC-susceptible EB treated with 3GC or BSA (defined as fourth-generation cephalosporins, carbapenems, and piperacillin/tazobactam) as definitive therapy. The primary outcome was 28-day mortality. The secondary outcome was the emergence of antimicrobial-resistant strain during antimicrobial therapy. We compared outcomes using the propensity scores and inverse-probability-weighting (IPW) adjustment to decrease the confounding by indication.

    Results: We identified 320 patients with EB; of these, 191 cases were eligible (86 treated with 3GC and 105 treated with BSA). All the measured covariates were well balanced after the IPW adjustment. We observed no significant differences in the unadjusted mortality [5.8% in the 3GC group vs. 13.3% in the BSA group; risk difference, −7.5%; 95% confidence interval (CI): -15.7–0.6; p = 0.09], and the IPW-adjusted mortality (5.1% vs. 9.4%; risk difference −4.3%; 95% CI: −12.2–3.5; p = 0.3) between the groups. The results of the propensity score-matched analysis and sensitivity analysis were similar. Furthermore, we did not observe the emergence of antimicrobial resistance during antimicrobial therapy in both groups.

    Conclusion: Definitive therapy with 3GC for susceptible EB was not associated with an increased risk of the 28-day mortality after adjustment for potential confounders with the propensity score analysis or with the emergence of antimicrobial-resistant strain.

    Satoshi Hayano, MD, Dept. of Infectious Diseases, Kameda Medical Center, Kamogawa, Japan, Shungo Yamamoto, MD, Department of Healthcare Epidemiology, School of Public Health in the Graduate School of Medicine, Kyoto University, Kyoto City, Kyoto, Japan, Ryota Hase, MD, Department of Infectious Diseases, Narita Red Cross Hospital, Narita, Chiba, Japan, Akihiro Toguchi, bachelor, Department of Laboratory Medicine, Kameda Medical Center, Kamogawa, Japan, Yoshihito Otsuka, PhD, Department of Laboratory Medicine, Kameda Medical Center, Kamogawa, Chiba, Japan and Naoto Hosokawa, M.D., Department of Infectious Diseases, Kameda Medical Center, Kamogawa, Chiba, Japan


    S. Hayano, None

    S. Yamamoto, None

    R. Hase, None

    A. Toguchi, None

    Y. Otsuka, None

    N. Hosokawa, None

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.